{"id":"rosuvastatin-improvement-of-lipid-profile","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Myalgia (muscle pain)"},{"rate":"3-4","effect":"Headache"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"1-2","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1160316","moleculeType":"Small molecule","molecularWeight":"1309.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosuvastatin is a competitive inhibitor of HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis. By blocking this enzyme, the drug decreases hepatic cholesterol production, leading to upregulation of LDL receptors on hepatocytes and increased clearance of LDL particles from the bloodstream. This results in significant reductions in total cholesterol, LDL cholesterol, and triglycerides, with modest increases in HDL cholesterol.","oneSentence":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides while raising HDL cholesterol.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:08.560Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and mixed dyslipidemia"},{"name":"Primary prevention of cardiovascular disease in at-risk patients"},{"name":"Secondary prevention of cardiovascular events in patients with established coronary heart disease"}]},"trialDetails":[{"nctId":"NCT00262548","phase":"PHASE4","title":"C-Reactive Protein (CRP) in Obese Diabetic Women","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Diabetes Mellitus, Type 2","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rosuvastatin; improvement of lipid profile","genericName":"Rosuvastatin; improvement of lipid profile","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides while raising HDL cholesterol. Used for Hypercholesterolemia and mixed dyslipidemia, Primary prevention of cardiovascular disease in at-risk patients, Secondary prevention of cardiovascular events in patients with established coronary heart disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}